Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Stock Option (Right To Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-50,000Price:--
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-34,180Price:$63.63
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,820Price:$62.92
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:50,000Price:$6.32
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Stock Option (Right To Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-75,000Price:--
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,200Price:$63.73
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-33,827Price:$62.96
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-39,973Price:$62.25
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:75,000Price:$6.32
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Rubinstein JulieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
Filings by filing date
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Stock Option (Right To Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-50,000Price:--
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-34,180Price:$63.63
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-15,820Price:$62.92
- Jan 13, 2021 (filed on Jan 15, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:50,000Price:$6.32
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Stock Option (Right To Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-75,000Price:--
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,200Price:$63.73
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-33,827Price:$62.96
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-39,973Price:$62.25
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Cohen Chad MOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:75,000Price:$6.32
- Jan 12, 2021 (filed on Jan 13, 2021)Insider Name:Rubinstein JulieOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-15,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1551 Eastlake Ave E Ste 200 SEATTLE WA 98102-7402 |
Tel: | N/A |
Website: | https://www.adaptivebiotech.com |
IR: | See website |
Key People | ||
Chad M. Robins Executive Chairman, Chief Executive Officer, Co-Founder | Charles Snag Senior Vice President - Clinical Diagnostics | Julie Rubinstein President |
Harlan S. Robins Co-Founder, Chief Scientific Officer | Chad M. Cohen Chief Financial Officer | Francis Lo Chief People Officer |
Stacy Taylor Senior Vice President, General Counsel | Sharon Benzeno Senior Vice President - Drug Recovery | Nancy Louise Hill Senior Vice President - Operations | Jyoti Palaniappan Senior Vice President - Clinical Diagnostics immunoSEQ Dx |
Business Overview |
Adaptive Biotechnologies Corp is a biotechnology company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform generates clinical immunomics data to decode the adaptive immune system. Its products and pipeline includes immunoSEQ, clonoSEQ and cellular therapy. It offers its immunoSEQ technology as a service and a kit. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). clonoSEQ is its diagnostic test product for the detection and next-generation sequencing (NGS)-based monitoring of minimal residual disease (MRD) in bone marrow samples in patients with myeloma (MM) and acute lymphoblastic leukemia (ALL). clonoSEQ is designed to sequence all rearranged receptor sequences in a tumor in parallel to enable MRD monitoring. It also focuses on developing immune-mediated therapies in oncology and other disease areas. |
Financial Overview |
For the nine months ended 30 September 2020,Adaptive Biotechnologies Corp revenues increased 12% to$68.2M. Net loss applicable to common stockholdersincreased from $49M to $101.7M. Revenues reflectDevelopment revenue segment increase of 45% to $39.5M.Higher net loss reflects Research and development -Balancing val increase of 59% to $74.3M (expense). |
Employees: | 453 as of Dec 31, 2019 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $8,144M as of Sep 30, 2020 |
Annual revenue (TTM): | $92.41M as of Sep 30, 2020 |
EBITDA (TTM): | -$124.57M as of Sep 30, 2020 |
Net annual income (TTM): | -$122.27M as of Sep 30, 2020 |
Free cash flow (TTM): | -$148.48M as of Sep 30, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 136,772,417 as of Oct 31, 2020 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |